MPOX
JOIN

Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment

The Brighton Collaboration Benefit-Risk Assessment of VAccines by TechnolOgy (BRAVATO) was formed to evaluate the safety and other key features of new platform technology vaccines. This manuscript reviews key features of the ChAdOx1-vectored vaccines.

Access the publication here >

More SAFETY TEMPLATES

Standardized template with key considerations for a benefit/risk assessment for the emergent vesicular stomatitis virus (VSV) viral vector vaccine for Lassa fever

June 2, 2025

Comirnaty COVID-19 mRNA vaccine: standardized template with key considerations for a benefit-risk assessment

August 27, 2024

Novavax COVID-19 Vaccine (NVX-CoV2373), a recombinant spike protein vaccine with Matrix-M adjuvant to prevent disease caused by SARS-CoV-2 viruses

October 26, 2023

Live-attenuated viral vaccines: standardized template for collection of key information for benefit-risk assessment

October 13, 2023

Viral vector vaccines: standardized template for collection of key information for benefit-risk assessment

October 13, 2023

Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment

October 13, 2023
View All

More Safety Templates

Email:
bc-coordinator@taskforce.org

Address:
The Task Force for Global Health,
330 W. Ponce de Leon Ave.
Decatur, GA 30030

Linkedin

© Brighton Collaboration  2023. All rights reserved.